Galenic Development and Pharmacokinetic Profile of Indapamide Sustained Release 1.5mg

In accordance with international guidelines recommending the use of low doses of antihypertensive agents, a new formulation of indapamide — indapamide sustained release (SR) — has been developed. Indapamide has been used worldwide for many years as an immediate release (IR) formulation at a dose of 2.5mg. The IR formulation leads to plasma peaks of indapamide immediately after administration of the tablet. These peaks are responsible for possible unfavourable electrolyte or metabolic effects relating to indapamide blood concentrations. The SR formulation, by eliminating plasma peaks, allows a smoothing of the pharmacokinetic profile of indapamide.